Core Viewpoint - The company reported a revenue of 4.446 billion yuan (+9.1% YoY) and a net profit of 598 million yuan (-12.6% YoY) for 2024, indicating a stable performance despite external pressures on the industry [2]. Group 1: Hospital Business Performance - The hospital segment achieved a revenue of 4.323 billion yuan in 2024, reflecting a year-on-year growth of 11.1%, with outpatient and inpatient services generating 1.633 billion yuan and 2.690 billion yuan, respectively [3]. - As of the end of 2024, the company operates 16 hospitals, including 4 tertiary hospitals and 12 secondary hospitals, with 2 additional tertiary hospitals under construction across 13 cities in 8 provinces [3]. - Ongoing construction projects include the successful acceptance of Dezhou Haijia Hospital and the progressive development of several other hospital phases, with an anticipated total bed capacity exceeding 16,000 in the future [3]. Group 2: Innovation and Development - The company is focused on enhancing its oncology specialty capabilities and strengthening its talent system, promoting a collaborative development model of "medical education and research" to improve clinical and research capabilities [4]. - In addition to basic medical services, the hospitals are expanding into other healthcare demands, such as infertility treatment collaborations and improving the quality of aesthetic and dental services [4]. - The company is actively pursuing strategic partnerships with commercial insurance firms to enhance the medical payment system and is exploring the application of AI technology to optimize patient experiences [4].